Emergent Biosolutions ROA 2010-2022 | EBS

Current and historical return on assets (ROA) values for Emergent Biosolutions (EBS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Emergent Biosolutions ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $0.10B $2.74B 3.39%
2022-03-31 $0.16B $2.78B 5.45%
2021-12-31 $0.23B $2.96B 7.94%
2021-09-30 $0.23B $2.87B 7.85%
2021-06-30 $0.30B $2.92B 10.61%
2021-03-31 $0.39B $2.90B 14.28%
2020-12-31 $0.31B $2.88B 11.91%
2020-09-30 $0.17B $2.62B 6.90%
2020-06-30 $0.17B $2.47B 7.23%
2020-03-31 $0.07B $2.28B 2.89%
2019-12-31 $0.05B $2.33B 2.36%
2019-09-30 $0.00B $2.33B 0.18%
2019-06-30 $-0.02B $2.32B -0.91%
2019-03-31 $0.04B $2.15B 2.51%
2018-12-31 $0.06B $2.23B 4.49%
2018-09-30 $0.10B $1.17B 8.99%
2018-06-30 $0.11B $1.14B 10.51%
2018-03-31 $0.07B $1.07B 6.58%
2017-12-31 $0.08B $1.07B 8.27%
2017-09-30 $0.09B $1.02B 8.78%
2017-06-30 $0.07B $0.97B 7.64%
2017-03-31 $0.06B $0.95B 5.83%
2016-12-31 $0.05B $0.97B 5.11%
2016-09-30 $0.05B $0.93B 4.63%
2016-06-30 $0.06B $1.06B 6.14%
2016-03-31 $0.09B $1.04B 8.82%
2015-12-31 $0.06B $1.04B 6.40%
2015-09-30 $0.06B $0.98B 6.25%
2015-06-30 $0.04B $0.94B 4.80%
2015-03-31 $0.04B $0.92B 3.93%
2014-12-31 $0.04B $0.94B 4.27%
2014-09-30 $0.02B $0.87B 2.79%
2014-06-30 $0.01B $0.84B 1.80%
2014-03-31 $0.02B $0.82B 2.77%
2013-12-31 $0.03B $0.63B 5.18%
2013-09-30 $0.03B $0.60B 5.50%
2013-06-30 $0.03B $0.56B 4.55%
2013-03-31 $0.02B $0.54B 4.24%
2012-12-31 $0.02B $0.56B 4.47%
2012-09-30 $0.04B $0.54B 6.95%
2012-06-30 $0.03B $0.53B 6.09%
2012-03-31 $0.04B $0.52B 7.35%
2011-12-31 $0.02B $0.55B 4.74%
2011-09-30 $0.02B $0.51B 4.25%
2011-06-30 $0.03B $0.49B 6.99%
2011-03-31 $0.03B $0.47B 6.65%
2010-12-31 $0.05B $0.50B 13.38%
2010-09-30 $0.03B $0.37B 8.57%
2010-06-30 $0.02B $0.35B 5.33%
2010-03-31 $0.02B $0.34B 6.91%
2009-12-31 $0.03B $0.35B 9.60%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.482B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00